Phaseline

Companies › Nectin Therapeutics

Nectin Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTX-1088
anti-CD155 (PVR) monoclonal antibody
CD155Phase 1CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05378425NTX-1088Phase 1CancerOncologyDec 2026

Targets

CD155 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.